argenx

Therapeutische antilichamen voor ernstige auto-immuunziektes en kanker

VFB event – 28 September, 2018

Forward Looking Statements

THIS PRESENTATION HAS BEEN PREPARED BY ARGENX SE ("ARGENX" OR THE "COMPANY") FOR INFORMATIONAL PURPOSES ONLY AND NOT FOR ANY OTHER PURPOSE. NOTHING CONTAINED IN THIS PRESENTATION IS, OR SHOULD BE CONSTRUED AS, A RECOMMENDATION, PROMISE OR REPRESENTATION BY THE PRESENTER OR THE COMPANY OR ANY DIRECTOR, EMPLOYEE, AGENT, OR ADVISER OF THE COMPANY. THIS PRESENTATION DOES NOT PURPORT TO BE ALL-INCLUSIVE OR TO CONTAIN ALL OF THE INFORMATION YOU MAY DESIRE. THIS PRESENTATION ALSO CONTAINS ESTIMATES AND OTHER STATISTICAL DATA MADE BY INDEPENDENT PARTIES AND BY US RELATING TO MARKET SIZE AND GROWTH AND OTHER DATA ABOUT OUR INDUSTRY. THIS DATA INVOLVES A NUMBER OF ASSUMPTIONS AND LIMITATIONS, AND YOU ARE CAUTIONED NOT TO GIVE UNDUE WEIGHT TO SUCH ESTIMATES.

Safe Harbor: Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding our investigational product candidates and preclinical studies and clinical trials, and the status, plans, timing of expected data readouts and related presentations and related results thereof, including the design of our trials and the availability of data from them, the timing and achievement of our product candidate development activities, future results of operations and financial positions, including potential milestones, business strategy, plans and our objectives for future operations. When used in this presentation, the words "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "will," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions identify forward-looking statements. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company's control. Such risks include, but are not limited to: the impact of general economic conditions, general conditions in the biopharmaceutical industries, changes in the global and regional regulatory environments in the jurisdictions in which the Company does or plans to do business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company's current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our product candidates; final and quality controlled verification of data and the related analyses; the expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration and European Medicines Agency; the possibility of having to conduct additional clinical trials; our ability to obtain and maintain intellectual property protection for our product candidates; and our reliance on third parties such as our licensors and collaboration partners regarding our suite of technologies and product candidates. Further, even if regulatory approval is obtained, biopharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition. These statements are also subject to a number of material risks and uncertainties that are described in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation.

argenx 2021:
Geïntegreerd biotechbedrijf - wereldspeler in immunologie



Uitgebreide pijplijn met potentiële geneesmiddelen voor weesziektes

Kandidaatgeneesmiddel	Doelwit	Indicaties	Preklinisch	Fase 1	Fase 2	Fase 3	Registr	Mijlpaal
ARGX-113 Efgartigimod	FcRn	Myasthenia Gravis (MG)				adapt myasthenia gravis study		Resultaten 2H20
		Immuun Thrombocytopenie (ITP)				advance immune thrombocytopenia study		Start Ph3 IV 2H19
		Pemphigus Vulgaris (PV)						Topline resultaten 1H20
		Chronische Inflammatoire Demyeliniserende Polyneuropathie (CIDP)						Start Ph2 trial 2H19
		ENHANZE® SC						Resultaten YE19
ARGX-110 Cusatuzumab	CD70	Acute Myeloïde Leukemie (AML)			janssen			Ph2 trial: Janssen
ARGX-117	C2	Ernstige autoimmuunziektes IV/ENHANZE® SC						CTA filing YE19
ARGX-118	Galectin-10	Inflammatoire aandoeningen van de luchtwegen						Lead selectie

Efgartigimod in MG: Fase 3 wereldwijd uitgerold

Kandidaatgeneesmiddel	Doelwit	Indicaties	Preklinisch	Fase 1	Fase 2	Fase 3	Registr
ARGX-113 Efgartigimod	FcRn	Myasthenia Gravis (MG) Immuun Thrombocytopenie (ITP) Pemphigus Vulgaris (PV) Chronische Inflammatoire Demyeliniserende Polyneuropathie (CIDP) ENHANZE® SC				adapt myasthenia gravis study	
ARGX-110 Cusatuzumab	CD70	Acute Myeloïde Leukemie (AML)					
ARGX-117	C2	Ernstige autoimmuunziektes IV/ENHANZE® SC					
ARGX-118	Galectin-10	Inflammatoire aandoeningen van de luchtwegen					

- Fase 2 Efgartigimod data in MG patiënten gepubliceerd in *Neurology:*
  - *Klinische en duurzame verbetering van het ziektebeeld*
  - *Potentieel geneesmiddel goed getolereerd*
- Fase 3 wereldwijd uitgerold – 150 patiënten
  - *Data verwacht tegen 2H2020*
  - *Commerciële lancering verwacht in 2021*

Efgartigimod in ITP: Start fase 3 gepland voor 2H2019

Kandidaatgeneesmiddel	Doelwit	Indicaties	Preklinisch	Fase 1	Fase 2	Fase 3	Registr
ARGX-113 Efgartigimod	FcRn	Myasthenia Gravis (MG) Immuun Thrombocytopenie (ITP) Pemphigus Vulgaris (PV) Chronische Inflammatoire Demyeliniserende Polyneuropathie (CIDP) ENHANZE® SC				advance immune thrombocytopenia study	
ARGX-110 Cusatuzumab	CD70	Acute Myeloïde Leukemie (AML)					
ARGX-117	C2	Ernstige autoimmuunziektes IV/ENHANZE® SC					
ARGX-118	Galectin-10	Inflammatoire aandoeningen van de luchtwegen					

- Fase 2 Efgartigimod data in ITP patiënten
  - Efgartigimod veilig voor ITP patiënten
  - Klinisch betekenisvolle stijging van bloedplaatjes
  - Bevestiging: *pipeline-in-a-product* opportuniteit
- Fase 3 gepland voor 2H2019
  - IV en SC studie

Efgartigimod in PV: Fase 2 data verwacht 1H2019

Kandidaatgeneesmiddel	Doelwit	Indicaties	Preklinisch	Fase 1	Fase 2	Fase 3	Registr
ARGX-113 Efgartigimod	FcRn	Myasthenia Gravis (MG) Immuun Thrombocytopenie (ITP) Pemphigus Vulgaris (PV) Chronische Inflammatoire Demyeliniserende Polyneuropathie (CIDP) ENHANZE® SC					
ARGX-110 Cusatuzumab	CD70	Acute Myeloïde Leukemie (AML)					
ARGX-117	C2	Ernstige autoimmuunziektes IV/ENHANZE® SC					
ARGX-118	Galectin-10	Inflammatoire aandoeningen van de luchtwegen					

- Interim Fase 2 Efgartigimod data in PV patiënten
  - Efgartigimod veilig voor PV patiënten
  - Eerste signalen van *disease control*
- Topline data verwacht 1H2020

Efgartigimod in CIDP: Vierde indicatie, start fase 2 2H2019

Kandidaatgeneesmiddel	Doelwit	Indicaties	Preklinisch	Fase 1	Fase 2	Fase 3	Registr
ARGX-113 Efgartigimod	FcRn	Myasthenia Gravis (MG) Immuun Thrombocytopenie (ITP) Pemphigus Vulgaris (PV) Chronische Inflammatoire Demyeliniserende Polyneuropathie (CIDP) ENHANZE® SC					
ARGX-110 Cusatuzumab	CD70	Acute Myeloïde Leukemie (AML)					
ARGX-117	C2	Ernstige autoimmuunziektes IV/ENHANZE® SC					
ARGX-118	Galectin-10	Inflammatoire aandoeningen van de luchtwegen					

- Start fase 2 in 2H2019
- KOL event 2H2019: duiding van studiedesign

Samenwerkingen voor Cusatuzumab & ARGX-115 programma

Janssen

- Co-development van cusatuzumab programma
- Versnellen en verbreden van ontwikkelingsplan
- $300M voorafbetaling + $200M equity
- Janssen in driver seat voor fase 2 studie - ongoing

AbbVie

- Succesvol afronden van preklinische studies → $40M + $20M
- Start fase 1: eerste kankerpatiënten behandelt met ARGX-115 → $ 30M

Innovative Access Program

Succesformule

Innovative Access Program

argenx

Ontwikkelen van therapeutische antilichamen

Top Academische Labo's

Ontrafelen van biologie van het doelwit

- University Southhampton
- University Utrecht
- Bern University
- UCL-de Duve
- Ludwig Institute
- Penn University
- Columbia University
- Univesity Torino

First-in-class potentiële geneesmiddelen

EIGEN PRODUCTEN

ARGX-113
ARGX-110 (Co-dev Janssen)
ARGX-117
ARGX-118

SAMENWERKINGEN

ARGX-115 (AbbVie)
ARGX-112 (Leo Pharma)
ARGX-116 (Staten/Novo Nordisk)
ARGX-114 (AgomAb)

argenx vandaag

Late-stage immunologiebedrijf	Twee fase 3 studies tegen eind 2019
Eigen *pipeline-in-a-product* programma's	Potentieel voor verschillende indicaties
Proof-of-concept in 2 indicaties	Succes van *beachhead* indicatie de-risk concept
Validatie van kankersamenwerking	50% commerciële rechten voor cusatuzumab
Gevalideerd platform die pijplijn voedt	*Innovative Access Program* in actie

Vragen?